Effect of Hepatitis C Clearance on Insulin Resistance

NCT04457050 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Insulin Resistance
Hepatitis C

Interventions

DRUG: Sofosbuvir 400 milligram
DRUG: Daclatasvir 60 milligram
DRUG: Ribavirin 400 milligram
DRUG: Ledipasvir 90milligram/Sofosbuvir 400 milligram Tab

Sponsor

Alexandria University